Valeo Pharma Inc., a Canadian pharmaceutical company, announced today the appointment of Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer, effective January 18th, to augment its senior leadership team and support expansion of Valeo’s commercial activities. Mr. Fasano has also been elected to the Company’s Board of Directors effective as of today.
“It gives me true pleasure to welcome Frederic to the Valeo executive team in this important new role. He possesses extensive International pharmaceutical experience and his management skills are well suited to helping us build a leading innovative pharmaceutical company with a deep commitment to our selected therapeutic areas of focus”, said Steve Saviuk, CEO. “This increase in management depth, coupled with our solid foundation of products and people, positions us well for the dynamic growth we foresee in the coming years.”
In addition to continuing in his role as CEO of Valeo, Mr. Saviuk will assume the role of Vice-Chairman of Valeo’s Board of Directors. Mr. Richard MacKay remains Chairman of the Board.
Commenting on his newly appointed position as President and COO of Valeo, Frederic Fasano said, “I am very excited to join Steve and his team at such a pivotal time in the corporate development of Valeo”. He added “Valeo is very well positioned to become an anchor Canadian pharma company aiming at bringing innovative treatments to patients. Life sciences have been incredibly productive and disruptive in recent times and we at Valeo want to reinvent the way this amazing science is reaching patients.”
